Skip to main content
logo
Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
6.59
-0.09 (-1.35%)
Aug 28, 2026, 4:00 PM EDT - Market closed

Gyre Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Revenue
109.82116.59105.76113.45102.29
Revenue Growth
-3.38%10.24%-6.78%10.91%-
Gross Profit
103.01111.17101.87108.8197.5
Operating Income
-15.2611.4916.2319.219.2
Net Income
-19.915.0312.09-92.932.3
Earnings Per Share
-0.220.020.05-1.410.03
EPS Growth
--53.23%---

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Cash & Investments
74.852.4326.6733.5125.18
Total Debt
3.420.941.60.410.61
Net Cash (Debt)
71.3851.4925.0733.124.56
Net Cash Growth
34.75%105.34%-24.25%34.76%-
Net Cash Per Share
0.760.500.250.500.32

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Operating Cash Flow
-4.941.01-3.6425.8910.68
Capital Expenditures
-1.17-1.19-2.32-8.52-4.99
Free Cash Flow
-6.11-0.18-5.9617.385.69
Free Cash Flow Growth
---205.25%-

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Gross Margin
93.80%95.36%96.33%95.91%95.31%
Operating Margin
-13.90%9.86%15.35%16.93%9.00%
Pretax Margin
-20.30%12.38%21.95%-67.84%9.20%
Profit Margin
-18.13%4.31%11.43%-81.92%2.25%
FCF Margin
-5.56%-0.15%-5.63%15.32%5.56%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22
PE Ratio
-127.6585.93--
Forward PE
-32.84---
P/FCF Ratio
---113.23-
PS Ratio
6.365.509.8217.34-